Osteoporosis Flashcards

1
Q

What is osteoporosis?

A

“porous bone”

It is a metabolic bone disease characterized by:

  • low bone mineral density
  • microarchitecture disruption (impaired mineralization)
  • decreased bone strength
  • increased risks of fractures

(Due to excessive bone resorption - incr osteoclast activity and decreased bone formation - reduced osteoblast activity)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Causes for decreased bone mass

A
  • Age - osteoblast lose activity
  • Menopause - low estrogen increases bone resorption
  • Low serum calcium - malnutrition, malabsorption
  • Alcohol consumption - incr RANKL, incr oxidative stress, apoptosis of osteoblast
  • Smoking - dose and duration dependent, affects the metabolism of estrogen, incr RANKL
  • Physical inactivity - muscular skeletal not used, bone deposition dcr due to lack of stress, bone resorption increase
  • Malnutrition (e.g., anorexia, bariatric surgery/gastrosurgery) - IC10
  • Medication use
  • Secondary to other diseases
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are some medications that can cause decreased bone mass?

A
  • Chronic glucocorticoid use
  • Long-term PPI
  • Cancer chemotherapy
  • Immunosuppressants (cyclosporine)
  • Antiseizure medications (PHT, phenobarbital)
  • Aromatase inhibitors
  • GnRH agonist and antagonist
  • Heparin (anticoagulants)

How does glucocorticoid cause reduced bone mass?

  • Dcr calcium absorption from the gut through antagonism of Vit D
  • Accelerate bone resorption and inhibit bone formation through inducing the decrease in osteoblast differentiation and increasing apoptosis of osteoblasts and osteocytes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are some diseases that can cause reduced bone mass?

A
  • Endocrine disturbances (Cushing’s, hyperprolactinemia, hyperparathyroidism, hyperthyroidism, hypogonadism, diabetes mellitus)
  • GI disease
  • Marrow-related disorders
  • Organ transplantation
  • Genetic disorders
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Clinical manifestations/Presentation of osteoporosis

A
  1. Asymptomatic
  2. Often undiagnosed until presented with episode of low-trauma fragility fracture, can involve:
  • Spine (vertebral compression) - height loss of >=20% dcr in vertebral height; kyphosis - excessive curve of the spine, bending over
  • Hip (femoral neck)
  • Wrist (distal radius)
  • Humerus
  • Rib
  • Pelvis

Note that low-trauma fragility fractures means they occur as a result of minimal trauma such as fall from standing height or less, or no identifiable trauma

These bones consist mainly of spongy bones

  1. Fragility fracture can cause pain and disability, increase healthcare cost, NH placement, and mortality
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Histological features

A
  1. Fewer trabeculae in the spongy bone
  2. Thinning of cortical bone
  3. Widening of haversian canals

=> increase risk of fragility fracture

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Goals of osteoporosis treatment

A
  1. Prevent fracture - either recurrent future fracture or first fracture
  2. Improve QoL and reduce economic burden
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

[Determining who to screen]

Which group of individuals should be further assessed for risk factors for osteoporosis and fragility fractures?

What are the risk factors?

A

Assess the following individuals for osteoporosis and fracture risk (if any of the risk factors are present):

  • Post-menopausal women
  • Men >=65 years

Assess the following risk factors in the above population:

  • Family history of osteoporosis or fragility fractures
  • Previous fragility fracture
  • Ageing
  • Low body weight
  • Height loss (>2cm within 3y)
  • Early menopause (45y and younger)
  • Certain medications: e.g., chronic glucocorticoid (>5mg/day prednisolone or its equivalent for >3m in the past year)
  • Low calcium intake (<500mg/day)
  • Excessive alcohol intake (>2 units/day)
  • Smoking
  • Prolonged immobility
  • History of falls
  • Presence of diseases that can lower bone mineral density or increase fracture risk (e.g., DM, hypogonadism, inflammatory rheumatic diseases such as RA)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

[Determining who to screen]

Assessment for post-menopausal women:

A

OSTA score - osteoporosis self-assessment tool for Asians

= age in years - weight in kg

  • High risk >20: consider DXA scan as change of low BMD is high
  • Medium risk 0-20: consider DXA scan if any other risk factors for osteoporosis is present
  • Low risk <0: consider deferring DXA

If patient initially deemed low risk, reassess risk if there has been significant weight loss or any clinical risk factor development since the last visit, or if last assessment was >=5 years ago

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Diagnosis of osteoporosis:

When to start treatment?

A

Diagnosis (given by first 2 scenarios)
3 scenarios to start treatment:

  1. History of fragility fractures - DXA not required
  • that occurred spontaneously or from minor trauma that would not ordinarily result in fracture; at vertebral/hip/wrist/humerus/rib/pelvis
  • asymptomatic vertebral fracture can be identified as >=20% decrease in vertebral height
  1. Bone mineral density (BMD) measurement using DXA hip and/or spine
  • T-score =< -2.5 SD (osteoporosis)
  • T-score > -2.5 SD to <-1 (osteopenia)
  • T-score >= -1 (normal bone density)
  1. Osteopenia (T-score > -2.5 SD to <-1) + Frax score (10y probability risk) - not osteoporosis, but high risk hence start treatment
  • Major osteoporotic fracture >= 20%

or

  • Hip fracture (>=3%)

If patient initially deemed low risk, give lifestyle advice and reassess risk if there has been significant weight loss or any clinical risk factor development since the last visit, or if last assessment was >=5 years ago

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is a DXA scan, and how to use the results?

A

Dual-energy X-ray absorptiometry (T-score)

  • Scan at two places: 1. Hip (femoral neck) 2. Spine
  • Hip scan has higher predictive value for hip fracture and fracture risk
  • Spine scan is quick and preferred for assessing response to treatment, but not suitable for diagnosis in older people because of high prevalence of degenerative changes, which may artefactually incr BMD value

May consider adding Vertebral Fracture Assessment (VFA) or thoracolumbar (TL) X-ray to identify vertebral fractures in older adults with height loss or lower back pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Difference between T-score and Z-score

A

T-score compares BMD against a young adult reference population (ladies in the 20s)

Z-score compares BMD against expected BMD for patient’s age

  • Therefore, Z-score values are not as bad as T-score
  • Z-score of =< -2 SD suggests coexisting problems (e.g., glucocorticoid therapy, alcoholism) that can contribute to osteoporosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Clinical history, Physical Examination, and Labs required to exclude secondary causes of bone loss:

(E.g., esp if Z-score =< -2)

A

Common:

  • Creatinine - renal function affects choice of drug, also may indicate CKD-MBD
  • FBC - exclude other disorders such as malignancies and malabsorption
  • Corrected calcium
  • Vit D

Others:

  • Thyroid-stimulating hormone - hyperthyroidism
  • Erythrocyte sedimentation rate (ESR) - rheumatological disease
  • Alkaline phosphatase - liver disease, Paget’s disease
  • Serum phosphate
  • Spot urine calcium/creatinine ratio
  • Serum total testosterone - hypogonadism
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How to assess FRAX score?

FRAX score: 10y probability of developing a fracture

A

Risk factors used to calculate FRAX score:

  • Age
  • Sex
  • Weight
  • Height
  • Previous fracture
  • Parent fractured hip
  • Current smoking
  • Glucocorticoid (5mg daily Prednisolone for >3m)
  • Rheumatoid arthritis
  • Secondary osteoporosis
  • Alcohol 3 or more units per day
  • BMD - key in the worse one

Prior clinical vertebral fracture or hip fracture is an especially strong risk factor, fracture probability computed may be underestimated

Smoking, alcohol, glucocorticoids are dose-dependent risk factors, the higher the exposure, the greater the risk

RA is a risk factor for fracture, OA is protective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

When to refer to a specialist?

What are some considerations before referring?

A
  • CrCl <30ml/min (might suspect CKD-MBD)
  • Complex secondary cause
  • Patients with multiple fragility fractures AND very low DXA BMD (T-score < -3.0)
  • Patients who adhere to treatment and who experience multiple fragility fractures or continued bone loss (>4-5% deterioration in DXA BMD) after at least a year of treatment

Consider (for the last point above):

  • reviewing secondary causes of osteoporosis
  • switching to IV or SC therapy to negate problems of poor gut absorption or poor compliance with PO therapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

[Bisphosphonate treatment]

Place in therapy

A

First line: Alendronate/RIsedronate

(If PO cannot be taken, IV Zoledronic acid or SC Denosumab can be considered)

effect only noticeable with long-term, regular use

17
Q

[Bisphosphonate treatment]

When to start after a fragility fracture?

What if fragility fracture happens during BP treatment?

A

Start after 2 weeks of fragility fracture

  • as long as person has healed more or less, and is able to sit upright for at least 30min (may take longer 2-4 weeks if fracture is at the hip)
  • note that it is not feasible/reasonable to wait for complete healing as it may take months

If fragility fracture happens during BP treatment,

  • Evaluate and investigate cause of fracture
  • Typically do not discontinue unless there is concern that the fracture occurred because BP was not effective - consider switching to an alternative
  • this is different from if atypical femoral fracture occurs, whereby the approach is to discontinue bisphosphonates treatment as there is a risk of delayed fracture healing
18
Q

[Bisphosphonate treatment]

Treatment duration

A

Low fracture risk:

  • 5 years for PO
  • 3 years for IV

High fracture risk (T-score <-3.0, or developed osteoporotic fractures before/during therapy or multiple other fractures during therapy):

  • 10 years for PO
  • 6 years for IV

Note: there is no evidence to guide treatment beyond 10y

19
Q

[Bisphosphonate treatment]

Treatment monitoring

A

Consider DXA BMD at baseline, after 1-2 years of treatment (to established clinical effectiveness), and every 2-3 years thereafter

  • Typically repeat BMD every 2 years
  • Assess for significant DXA BMD deterioration of >4-5% compared to previous measurement and for any fracture occurring while on medication (including asymptomatic vertebral fractures)
  • Note that if BMD dcr, should still continue for 5y (PO)/3y (IV) as BP will still reduce fractures
20
Q

[Bisphosphonate treatment]

What to do after patient has completed 5y (PO) / 3y (IV)?

A

Reevaluate patients 5y after initiating oral BP or 3y after IV zoledronic acid for potential medication holiday

If high risk of fracture (T-score <-3.0, or developed osteoporotic fractures before/during therapy or multiple other fractures during therapy):

  • Continue PO up 10y, IV up 6y (no med holiday)
  • Also consider extending treatment if: age >=75y, history of hip or vertebra fracture, sustained fracture while on treatment, taking oral glucocorticoids

If low risk of fracture, consider medication holiday:

  • Discontinue, and assess BMD after 18m to 3y (~2y)
  • Restart treatment if fracture occurs or if absolute DXA BMD has decreased >4-5% compared to the previous measurement or if pt fulfills criteria again
21
Q

[Pharmacological treatment approach]

A

In postmenopausal women:

  • First line: Alendronate, Risedroante (PO BP)
  • If oral BP cannot be taken: IV Zoledronic acid, SC Denosumab
  • Others: Raloxifene, HRT
  • High cost: Teriparatide - usually used if very high risk, for vertebral fractures

Note that in men, Raloxifene and HRT cannot be used

22
Q

Other considerations in osteoporosis:

A
  1. Consider efficacy, safety, cost, convenience, patient preference
  2. Check serum calcium and 25-hydroxyvitamin D levels prior to starting pharmacologic therapy
  • Vit D >=20-30ng/mL or 50-75nmol/L but <50-100ng/mL or 125-250nmol/L
  1. Give adequate calcium and vit D supplementation during treatment
  2. Treatment monitoring:
  • Serum creatinine - renal impairment affects drug choice
  • Serum calcium - correct hypocalcemia
  • Serum 25(OH) Vit D - correct Vit D deficiency
23
Q

Non-pharmacological management strategies of osteoporosis:

A
  • Appropriate calcium intake
  • Optimize Vit D intake
  • Advise on exercise: appropriate weight-bearing, muscle-strengthening, and balance exercises such as walking, elastic band exercises, Tai Chi (30min, 2-3x a week) **prevent falls*
  • Advise on smoking cessation
  • Advise on appropriate alcohol intake (=<2 units per day - e.g., 1 can of beer or 1 glass of wine)
  • Limit caffeine intake (=<2 cups per day)
  • Educate on fall risk, home safety - handle bars in toilet, and footwear; impaired vision; medication review - avoid sedating antihistamines, BZDs, psychotropic, antidepressants, anticholinergics, codeine, anarex, antihypertensives
  • Educate patient about osteoporosis and fragility fractures and their implications
24
Q

Advise on appropriate calcium intake:

  • Requirement
  • Dosing
  • Benefit
  • Concerns
  • DDIs - ITFBT
A

Requirement:

  • 1000mg/day of elemental calcium for >50y
  • 800mg/day for 19-50y)
  • Consider supplementing if dietary <700mg/day
  • Split up dose for better absorption, take with food as GI acid enhances calcium absorption

Dosing:

  • Split into smaller doses for better absorption
  • Take with food as GI acid enhances calcium absorption

Benefits:

  • Small incr in BMD

Concerns:

  • GI SEs (constipation)
  • Nephrolithiasis
  • Incr CVD risk (?)

DDI:

  • PPI (dcr calcium absorption as acidic environment required for calcium absorption)
  • Fiber or bulk-forming laxatives (dcr calcium absorption)
  • Iron (dcr iron absorption due to chelation, space 2h apart)
  • Tetracyclines (dcr absorption of tetracyclines, space 2h apart)
  • Fluoroquinolones (dcr absorption of fluoroquinolones, space 2h apart)
  • Bisphosphonates (dcr absorption of BP, avoid pdts high in calcium, iron, magnesium - polyvalent cations within 30min of oral BP)
  • Thyroid supplements (dcr absorption of thyroid supplement, space 2h apart)
25
Q

Advice on Vit D intake

  • Requirement
  • Benefits
  • DDIs - RACAO
A

Requirement:

  • 600IU/day for >50y
  • 800 IU/day for >70y
  • Supplement 800IU/day cholecalciferol to those at risk of/have Vit D insufficiency
  • note that sunlight is a source of Vit D

Benefit:

  • Reduce falls and confers small reduction in fracture risk when combined with calcium supplements

DDI:

  • Rifampicin
  • Anticonvulsants (PHT, VPA, CBZ)
  • Cholestyramine (impair absorption of Vit D, dcr conc. of Vit D, space administration apart)
  • Orlistat (binds to fats and hence binds to fat soluble Vit D, dcr absorption of Vit D, space 2h apart)
  • Aluminium-containing products (incr absorption of aluminium)